FDA Not Forgetting Sanofi’s Previous Failed Trial In New Multaq Review
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA asks Cardiovascular and Renal Drugs advisory committee to compare Sanofi’s negative dronedarone trial to its new pivotal trial.